E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Atherogenic dyslipidaemic patients with abdominal obesity |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059179 |
E.1.2 | Term | Abdominal obesity |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10058110 |
E.1.2 | Term | Dyslipidemia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of GFT505 30 mg in reducing serum TG and increasing HDL-C levels compared with placebo in atherogenic dyslipidaemic patients with abdominal obesity. To assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 during 28 days. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of GFT505 30 mg in reducing LDL-C and non-HDL-C levels compared with placebo. To describe the changes in TG, HDL-C, LDL-C and non-HDL-C levels in the two groups. To describe the changes in other lipid parameters in the two groups. To describe the changes in inflammatory markers in the two groups (including changes of gene expression in leukocytes) To evaluate the effect of GFT505 30 mg on insulin sensitivity : OGTT (Oral Glucose Tolerance Test) and HOMA score. To assess the plasma exposure of GFT505 after repeated once daily administrations of GFT505. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provide written informed consent prior to enrolment 2. Male or post-menopausal female (defined as >12 months since last menstrual period and with stable (at least 6 months prior to screening) and continuous Hormonal Replacement Therapy if any – surgical removal of ovaries can be considered as “surgical menopause”) 3. Aged 18 to 75 years 4. Atherogenic dyslipidaemia inadequately controlled despite Therapeutic Lifestyle Change (TLC) recommendations (diet and exercise)* - *(documented or highly probable at V1) 5. Waist circumference ≥ 102 cm for men, ≥ 88 cm for women 6. Non-hypertensive or patient taking antihypertensive medication maintained at a stable dose for 2 months at least prior to screening (and the stable dose can be maintained throughout the study) 7. Fasting TG ≥ 200 mg/dL and ≤ 500 mg/dL (2,28 mmol/L ≤ TG ≤ 5,65 mmol/L) at V2 8. Fasting HDL-C ≤ 40 mg/dL (≤ 1.03 mmol/L) for men, HDL-C ≤ 50 mg/dL (≤ 1.29 mmol/L) for women at V2 9. Fasting LDL-C < 190 mg/dL (< 4.91 mmol/L) at V2 10. Patient agrees to come to following visits and it is possible to schedule V4 and V5 inside the protocol specified range (14 days +/- 2 days between V3 and V4 ; 14 days +/- 2 days between V4 and V5) |
|
E.4 | Principal exclusion criteria |
1. Body Mass Index (BMI) ≥ 35 kg/m² 2. Known clinical evidence of Coronary Artery Disease prior to or at screening 3. Blood Pressure > 160 / 95 mmHg 4. Known alcohol and/or any other drug abuse or dependence. Alcohol consumption of more than 21 alcoholic beverages per week is considered abusive. One alcoholic beverage is defined as 30 mL distilled spirits, 120 mL wine, or 330 mL beer 5. Type I or Type II diabetes mellitus 6. Known homozygous familial hypercholesterolaemia or known Type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia) 7. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B or C 8. Known history of malignant disease (excluding treated basal cell carcinoma) 9. Patients who have serious or unstable medical or psychological conditions which, in the opinion of the Investigator, would lead the patient to be non-compliant or uncooperative during the study or would compromise the patient’s safety or successful participation in the study 10. Patients who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the 3 months following the end of the study 11. The Patient is a female of childbearing potential, is pregnant or lactating 12. Any medication that may interfere with study medication absorption, distribution, metabolism or excretion or could lead to induction or inhibition of microsomial enzymes within 3 months prior to the screening day 13. Currently taking other investigational drugs or who have taken part in a clinical trial within the previous month prior to screening 14. Patient having already taken GFT505 during his/her participation in a previous clinical trial 15. Known intolerance or contra-indication to the list of excipients of GFT505 (Gelatin, Lactose, Glycerol, Titanium dioxide, Red Iron dioxide) 16. Patient not covered by Health Insurance System and / or not in compliance with the recommendations of National Law in force 17. Patient who cannot be contacted in case of emergency 18. Uncontrolled hypothyroidism defined as TSH > 2 x the upper limit of normal (ULN) at V2 (thyroid dysfunction controlled for at least 6 months prior to screening is permitted) 19. Significant renal disease, including nephritic syndrome, chronic renal failure and/or serum creatinine >180µmol/L at V2 20. Active liver disease or hepatic dysfunction as defined by elevations in liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT) and alkaline phosphatases (ALP)] > 2 x the upper limit of normal (ULN) at V2 21. Unexplained serum creatine kinase (CPK) > 3 x the upper limit of normal (ULN) at V2. Patients with a reason for CPK elevation may continue in screening and have the measurement repeated prior to randomization; a repeat CPK > 3 x ULN is exclusionary 22. Patient for whom the wash-out period of lipid-regulating drugs (fibrates, statins and other classes of lipid-regulating drugs) has not been respected or who has taken any other drug that is known to affect the lipid metabolism |
|
E.5 End points |
E.5.1 | Primary end point(s) |
EFFICACY :
Primary Endpoint : - Decrease in serum TG level from baseline to D28 (V5) - Increase in serum HDL-C level from baseline to D28 (V5)
Secondary Endpoints : - Decrease in serum non-HDL-C and LDL-C levels from baseline to D28 (V5) - Changes from baseline to all study visits for other lipids (TG, HDL-C, Total Cholesterol, FFA) and special lipids (Apo AI, Apo AII, Apo B, Apo CIII, Apo CIII/B, Apo CIII-nonB, small dense LDL, remnants) - Changes from baseline to D28 (V5) for inflammatory markers : hsCRP, TNF-a, IL-6, PAI-1, fibrinogene, gene expression in leukocytes - Changes from baseline to all study visits for plasma glucose metabolism : fasting plasma glucose, insulin, HOMA score - Changes from baseline to D28 (V5) for OGTT (Oral Glucose Tolerance Test) - Changes from baseline to D28 (V5)for adiponectin and leptin levels
SAFETY : - SAE, AE, physical examination, vital signs, medical history, ECG - Hematology (WBC and differential count, RBC, hemoglobin, hematocrit and platelets, haptoglobin, prothrombin, reticulocytes count) and biochemical markers (fasting plasma glucose, insulin, CPK, AST, ALT, GGT, TSH, alkaline phosphatases, creatinine, troponin, total and conjugated bilirubin, urea, uric acid, albumin, homocystein, fibrinogen, total proteins, electrolytes (sodium, potassium, chloride, calcium)) and urinalysis. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 39 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial corresponds to the last patient last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |